
Targeted Therapies Broaden Treatment Options for CDK4/6 Inhibitor–Resistant, HR+ Breast Cancer
Molecular testing is becoming increasingly important for refining targeted treatment approaches for patients with hormone receptor–positive, HER2-negative metastatic breast cancer, a setting in which several agents have been recently approved and …